{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:16Z","timestamp":1792979896137,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"ViiV Healthcare K.K.","id":[{"id":"https:\/\/ror.org\/01cc9yk21","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03544-0","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T07:50:58Z","timestamp":1774857058000},"page":"2527-2549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Effectiveness Analysis of Dolutegravir and Dolutegravir\/Abacavir\/Lamivudine in Japanese People Living with HIV: 10\u00a0years of Post-Marketing Surveillance"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8616-8835","authenticated-orcid":false,"given":"Akemi","family":"Sebata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1154-7090","authenticated-orcid":false,"given":"Takako","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8195-0594","authenticated-orcid":false,"given":"Yuko","family":"Maeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5027-250X","authenticated-orcid":false,"given":"Yoichiro","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Ibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5855-2084","authenticated-orcid":false,"given":"Akiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"3544_CR1","unstructured":"Joint United Nations Programme on HIV\/AIDS. The urgency of now: AIDS at a crossroads. 2024. https:\/\/www.unaids.org\/en\/resources\/documents\/2024\/global-aids-update-2024. Accessed 29 Apr 2025."},{"key":"3544_CR2","unstructured":"AIDS Prevention Information Network. AIDS incidence trend annual report 2023. [in Japanese] https:\/\/api-net.jfap.or.jp\/status\/japan\/nenpo2023.html. Accessed 29 Apr 2025."},{"key":"3544_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.35772\/ghm.2021.01120","volume":"4","author":"S Oka","year":"2022","unstructured":"Oka S. Aids at 40th: the progress of HIV treatment in Japan. Global Health & Medicine. 2022;4:1\u20138.","journal-title":"Global Health & Medicine"},{"key":"3544_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25449","volume":"23","author":"D Back","year":"2020","unstructured":"Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc. 2020;23:e25449.","journal-title":"J Int AIDS Soc"},{"key":"3544_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40121-014-0029-7","volume":"3","author":"DE Dow","year":"2014","unstructured":"Dow DE, Bartlett JA. Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV. Infectious Diseases and Therapy. 2014;3:83\u2013102.","journal-title":"Infectious Diseases and Therapy"},{"key":"3544_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-022-00608-1","volume":"19","author":"AV Zhao","year":"2022","unstructured":"Zhao AV, Crutchley RD, Guduru RC, Ton K, Lam T, Min AC. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. Retrovirology. 2022;19:22.","journal-title":"Retrovirology"},{"key":"3544_CR7","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Updated 25 Sep 2025. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed 1 Oct 2025."},{"key":"3544_CR8","unstructured":"European AIDS Clinical Society. EACS Guidelines v12.1. 2024. https:\/\/eacs.sanfordguide.com. Accessed 30 Apr 2025."},{"key":"3544_CR9","unstructured":"Research Group Aiming to Build Team Medical Care and Improve Medical Standards for HIV Infection and Hemophilia. Anti-HIV treatment guideline 2025. [in Japanese] https:\/\/hiv-guidelines.jp\/index.htm. Accessed 30 Apr 2025."},{"key":"3544_CR10","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240031593. Accessed 30 Apr 2025."},{"key":"3544_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jama.2024.24543","volume":"333","author":"RT Gandhi","year":"2025","unstructured":"Gandhi RT, Landovitz RJ, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel. JAMA. 2025;333:609\u201328.","journal-title":"JAMA"},{"key":"3544_CR12","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1097\/QAD.0b013e3283612419","volume":"27","author":"HJ Stellbrink","year":"2013","unstructured":"Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS. 2013;27:1771\u20138.","journal-title":"AIDS"},{"key":"3544_CR13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","volume":"381","author":"F Raffi","year":"2013","unstructured":"Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735\u201343.","journal-title":"Lancet"},{"key":"3544_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","volume":"13","author":"F Raffi","year":"2013","unstructured":"Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13:927\u201335.","journal-title":"Lancet Infect Dis"},{"key":"3544_CR15","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","volume":"383","author":"B Clotet","year":"2014","unstructured":"Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222\u201331.","journal-title":"Lancet"},{"key":"3544_CR16","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","volume":"2","author":"JM Molina","year":"2015","unstructured":"Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2:e127\u201336.","journal-title":"Lancet HIV"},{"key":"3544_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","volume":"70","author":"S Walmsley","year":"2015","unstructured":"Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70:515\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3544_CR18","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","volume":"382","author":"P Cahn","year":"2013","unstructured":"Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700\u20138.","journal-title":"Lancet"},{"key":"3544_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/infdis\/jis750","volume":"207","author":"JJ Eron","year":"2013","unstructured":"Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis. 2013;207:740\u20138.","journal-title":"J Infect Dis"},{"key":"3544_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/infdis\/jiu051","volume":"210","author":"A Castagna","year":"2014","unstructured":"Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210:354\u201362.","journal-title":"J Infect Dis"},{"key":"3544_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3851\/IMP2878","volume":"20","author":"B Akil","year":"2015","unstructured":"Akil B, Blick G, Hagins DP, et al. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther. 2015;20:343\u20138.","journal-title":"Antivir Ther"},{"key":"3544_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3851\/IMP3166","volume":"22","author":"B Trottier","year":"2017","unstructured":"Trottier B, Lake JE, Logue K, et al. Dolutegravir\/abacavir\/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, phase IIIb study. Antivir Ther. 2017;22:295\u2013305.","journal-title":"Antivir Ther"},{"key":"3544_CR23","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1007\/s12325-021-01842-3","volume":"38","author":"H Hongo","year":"2021","unstructured":"Hongo H, Nagao T, Nakamura K, et al. Safety and effectiveness analysis of dolutegravir in patients with HIV-1: interim report of post-marketing surveillance in Japan. Adv Ther. 2021;38:4480\u2013504.","journal-title":"Adv Ther"},{"key":"3544_CR24","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1001\/jama.290.11.1510","volume":"290","author":"MR Golden","year":"2003","unstructured":"Golden MR, Marra CM, Holmes KK. Update on syphilis: resurgence of an old problem. JAMA. 2003;290:1510\u20134.","journal-title":"JAMA"},{"key":"3544_CR25","first-page":"67","volume":"22","author":"K Fukushima","year":"2020","unstructured":"Fukushima K. HIV infection and syphilis. J AIDS Res. 2020;22:67\u201376 ([in Japanese]).","journal-title":"J AIDS Res"},{"key":"3544_CR26","unstructured":"Triumeq Combination Tablets [package insert (8th edition), in Japanese]. Tokyo, Japan: ViiV Healthcare K.K; 2024. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/166272_6250106F1021_1_21. Accessed 22 Dec 2025."},{"key":"3544_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/QAI.0000000000001269","volume":"74","author":"A Fettiplace","year":"2017","unstructured":"Fettiplace A, Stainsby C, Winston A, et al. Psychiatric symptoms in patients receiving dolutegravir. J Acquir Immune Defic Syndr. 2017;74:423\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3544_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.24875\/AIDSRev.19000023","volume":"21","author":"C Hoffmann","year":"2019","unstructured":"Hoffmann C, Llibre JM. Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors. AIDS Rev. 2019;21:4\u201310.","journal-title":"AIDS Rev"},{"key":"3544_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-11090-3","volume":"25","author":"N Squillace","year":"2025","unstructured":"Squillace N, Ricci ED, Orofino G, et al. Neuropsychiatric adverse events in people with HIV initiating a new integrase strand transfer inhibitor-based regimen in Italy: findings from the NEURO-INSTI study. BMC Infect Dis. 2025;25:763.","journal-title":"BMC Infect Dis"},{"key":"3544_CR30","doi-asserted-by":"crossref","unstructured":"D:A:D Study Group; Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417\u201326.","DOI":"10.1016\/S0140-6736(08)60423-7"},{"key":"3544_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/QAI.0b013e31819ff0e6","volume":"51","author":"CH Brothers","year":"2009","unstructured":"Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51:20\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3544_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/QAI.0b013e31826f993c","volume":"61","author":"X Ding","year":"2012","unstructured":"Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012;61:441\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3544_CR33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/2047487315579291","volume":"23","author":"N Friis-M\u00f8ller","year":"2016","unstructured":"Friis-M\u00f8ller N, Ryom L, Smith C, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the data-collection on adverse effects of anti-HIV drugs (D:A:D) study. Eur J Prev Cardiol. 2016;23:214\u201323.","journal-title":"Eur J Prev Cardiol"},{"key":"3544_CR34","unstructured":"World Health Organization. HIV drug resistance: Brief report 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240086319. Accessed: 22 Dec 2025."},{"key":"3544_CR35","doi-asserted-by":"publisher","DOI":"10.52225\/narra.v4i3.1022","volume":"4","author":"FA Djojosugito","year":"2024","unstructured":"Djojosugito FA, Arfianti A, Wisaksana R, et al. Prevalence of major INSTI and HIV-1 drug resistance mutations in pre- and antiretroviral-treated patients in Indonesia. Narra J. 2024;4:e1022.For the N values and four-digit numbers in the figure, I think it would be fine to remove the commas to match the main text.","journal-title":"Narra J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03544-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03544-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03544-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:51:39Z","timestamp":1780116699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03544-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3544"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03544-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Akemi Sebata, Takako Nagao, Tomoko Matsukawa, Yuko Maeno, Miwako Suzuki, Yoichiro Yoshikawa, Shiro Ibe, Akiko Fukuda and Dong Wang are employed by ViiV Healthcare K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This post-marketing surveillance has been conducted by CMIC HOLDINGS Co., Ltd. on behalf of ViiV Healthcare K.K. in compliance with the relevant Japanese regulations (Ministerial Ordinance on GPSP; MHLW No. 171 of December 20, 2004, the amended ordinance, and the related notifications). The study protocol was reviewed and approved by the PMDA, the Japanese regulatory authority, and subsequently approved by the ethics committees at each participating study site. Under the GPSP regulations, written informed consent from patients is not required in post-marketing surveillance. However, the protocol specified that aggregated and analyzed results may be disseminated in scientific reports. Prior to treatment initiation, each potential participant received a detailed explanation regarding the use of the single-agent DTG or DTG\/ABC\/3TC, and verbal consent for therapy was obtained from all individuals before enrollment. All collected data were anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}